SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $154

Credit Suisse analyst Tiago Fauth maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $149 to $154.

Benzinga · 05/20/2020 12:24

Credit Suisse analyst Tiago Fauth maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $149 to $154.